Satsuma Pharmaceuticals has raised $62 million in a Series B preferred stock financing, led by Wellington Management Company.
Other existing investors in this Series B funding included RA Capital Management, TPG Biotech and Shin Nippon Biomedical. Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures and SBI Investment were new investors.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!